QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Veracyte, Inc. (VCYT)

Healthcare

No action
Fundamental
4
Sentiment
2
Technical
1

Do Nothing: qualitativeScore is 2 (below the required floor of 3) - the upstream qualitative screen flagged a red flag serious enough to disqualify a fresh long - and the overnight-gap gate fails as well (regular close 52.45 on 2026-11-04 to regular open 29.59 on 2026-11-05, a ~43.7% gap versus the 5% ceiling), so the protective stop cannot cover the earnings-driven off-hours repricing; with price 46% below the SMA50 and ADX 36 in a broken downtrend, neither a pullback/oversold limit nor a breakout stop qualifies.

Analysis as of 2026-11-06· more than 2 trading days ago

Company overview

Veracyte, Inc. is a diagnostics company offering genomic classifiers for cancer diagnosis, including thyroid, prostate, bladder, breast, and lung cancers. It also provides the nCounter analysis system services. Headquartered in South San Francisco, California, the company was incorporated in 2006.

Fundamental

good
Fundamental4
Solid fundamentals

Veracyte maintains strong fundamentals with a debt-free balance sheet and robust cash flow, despite recent margin compression and guidance cuts.

Debt-free diagnostics franchise with low-70s gross margins, $581.8 million of trailing revenue growing mid-teens, $161.9 million of trailing free cash flow and $370.5 million of cash and investments - offset by a Q3 2026 operating-margin reset (operating income -28% on operating expenses +32%), trimmed testing-revenue guidance with Decipher Prostate volumes below plan, and a 54% one-day share-price collapse. At roughly 15x trailing earnings, 3x sales and 10x adjusted EBITDA with an 8.4% free-cash-flow yield and DCF values 57-68% above the current price, the risk/reward reads constructive provided the margin investment stabilizes. No dividend is paid.

Sentiment

weak
Sentiment2
Negative sentiment

Market sentiment turned negative following a significant share price drop due to a guidance reset and volume shortfall.

Dominant driver is the 2026-11-04 Q3 print and FY2026 testing-guidance reset (announced), read bearish on market reception — a ~54% single-session collapse to a 52-week low on ~10x normal volume with a Leerink downgrade to Market Perform — against a measured sentiment delta that has turned decisively negative (baseline polarity_score ≈ +0.26 across 16 scored items versus ≈ -0.20 across 7 in the scoring window, a swing of roughly -0.47). Moderate red-flag cap applied for sharp ≤14-day sentiment deterioration and for a tested-but-unbalanced catalyst conflict; the severe screen is clean (no regulator-confirmed action, no going concern, no dilutive or distress raise), but with an empty forward calendar inside 30 days and no market-rewarded bullish offset the setup is weak and forming at best.

Technical

very weak
Technical1
Broken downtrend

The stock is in a downtrend with no immediate technical support, following a sharp price decline.

Broken post-crash structure, not a tradable long: price 24.00 sits below sma20 45.95, sma50 44.50, sma200 42.86, ema9 44.64, ema21 45.66 and the 2026-11-05 VWAP 26.32 after a single-session -54.3% repricing. RSI14 24.51 and Williams %R -93.23 are deeply oversold but are bounce-only readings inside a live downtrend; MACD line -0.32 crossed under signal 0.99 (histogram -1.31) and under zero, and ADX14 36.02 and rising with price below every average marks a strong DOWN trend, not an up trend. ATR14 4.48 is 18.7% of price, volume was capitulation-sized (14.99M shares, ~10x normal). The chart scores 1/5 and the entry is independently blocked at Step 00 by the qualitative floor (qualitativeScore 2 < 3) and by the overnight-gap gate (43.6% overnight gap).

You’re looking at 2026-11-06 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.